文献速递生殖医学妇科

美国接受子宫移植的绝对子宫因素不孕患者的体外受精实践

In vitro fertilization practice in patients with absolute uterine factor undergoing uterus transplant in the United States.
PubMed 文献 · Fertil Steril · 2024-04-15

该队列研究汇总了美国三项持续最久的子宫移植临床试验中31例子宫移植受者的体外受精经验。移植前平均行2次取卵,移植后19%(6/31)受者需再次取卵;共72次自体单胚胎移植,每次移植的活产率为35%(25/72),首次移植后活产率为57%(13/23),第二次移植后升至74%(17/23)。

要点

  • 移植前平均取卵2次(范围1-4),平均冻存8枚未检测胚胎或6枚整倍体胚胎。
  • 移植后19%(6/31)受者需取卵,共16个周期,均经阴道穿刺且无并发症。
  • 每次胚胎移植的活产率为35%(25/72),首次移植后为57%(13/23),第二次后为74%(17/23)。

核心结论

  • 尽管胚胎植入前遗传学检测和移植前胚胎冷冻保存使用率高,移植后仍有26%(6/23)至少完成一次胚胎移植的受者需要卵巢刺激。
  • 移植后取卵均经阴道完成且无并发症。
  • 未来报告体外受精治疗经验对优化子宫移植后的生殖结局至关重要。

研究设计与样本

  • 队列研究,纳入美国三项持续最久的子宫移植临床试验中的31例子宫移植受者,移植时平均年龄31±4.7岁。

主要发现

  • 移植前平均取卵2次(范围1-4),平均冻存8枚未检测胚胎(范围3-24)或6枚整倍体胚胎(范围2-10)。
  • 移植后19%(6/31)受者需取卵,共16个周期(每受者2-4个周期),均经阴道完成且无并发症。
  • 74%(23/31)受者使用胚胎植入前遗传学检测。
  • 23例至少完成一次胚胎移植的患者共行72次自体单胚胎移植,其中2次为新鲜周期移植,70次为冻胚移植。
  • 内膜准备中程序化方案(外源性雌激素和孕激素)61次,自然周期方案9次。

关键数值与推荐

  • 每次胚胎移植的总体活产率为35%(25/72)。
  • 在21例通过胚胎移植获得活产的患者中,平均行2.2次胚胎移植。
  • 首次胚胎移植后总体活产率为57%(13/23),第二次移植后升至74%(17/23)。
  • 程序化方案与自然周期冻胚移植在子痫前期、活产、新生儿出生或胎盘重量方面无差异。
  • 活体与 deceased 供体子宫的活产率无差异(37% vs. 32%)。

临床怎么用

  • 移植后卵巢刺激在至少完成一次胚胎移植的受者中占26%(6/23)。
  • 移植后取卵可经阴道完成且无并发症。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report detailed, pooled multicenter experiences and outcomes after in vitro fertilization (IVF) treatment among patients undergoing uterus transplantation (UTx) in the US. DESIGN: Cohort study. SETTING: Hospital. PATIENTS: Patients undergoing UTxsfrom the three longest-running UTx clinical trials in the US. INTERVENTION: In vitro fertilization treatment among patients undergoing UTx. MAIN OUTCOME MEASURES: Reproductive outcomes pretransplant and posttransplant ovarian stimulation. RESULTS: Thirty-one uterus transplant recipients were included in this cohort (mean [±SD] age at transplant was 31 ± 4.7 years). Before transplant, recipients completed a mean of two oocyte retrievals (range 1-4), banking a mean of eight untested embryos (range 3-24) or six euploid embryos (range 2-10). Posttransplant retrieval cycles were required in 19% (n = 6/31) of recipients, for a total of 16 cycles (range 2-4 cycles per recipient). All posttransplant retrievals were performed vaginally without complications. Preimplantation genetic testing was used by 74% (n = 23/31) of subjects. Seventy-two autologous single embryo transfers (ETs) occurred in 23 patients who completed at least one ET. Two ETs followed a fresh IVF treatment cycle, and the remainder (n = 70) were frozen ETs. Endometrial preparation was more commonly performed with programmed protocols (n = 61) (exogenous administration of estrogen and progesterone) compared with natural cycle protocols (n = 9). The overall live birth rate (LBR) for this cohort was 35% (n = 25/72) per ET. Among those patients (n = 21) who had an ET leading to a live birth, a mean of 2.2 ETs were performed. The overall LBR after the first ET was 57% (n = 13/23) and rose to 74% (n = 17/23) after a second ET. There was no difference in rate of preeclampsia, live birth, neonatal birth, or placental weights among programmed vs. natural cycle frozen ETs. There were no differences in the LBR between living or deceased donor uteri (37% vs. 32%). CONCLUSIONS: Posttransplant ovarian stimulation was required in 26% (n = 6/23) of recipients undergoing at least one ET, despite high rates of preimplantation genetic testing and pretransplant embryo cryopreservation. Posttransplant retrievals were performed transvaginally, without complications. Future reporting of IVF treatment experiences will be essential to optimizing reproductive outcomes after a uterus transplant. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02656550 (Baylor University Medical Center); NCT03307356 (University of Pennsylvania); and NCT02573415 (Cleveland Clinic).

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Walter JR, Johannesson L, Falcone T, et al. In vitro fertilization practice in patients with absolute uterine factor undergoing uterus transplant in the United States. Fertil Steril. 2024. PMID: 38631504. doi:10.1016/j.fertnstert.2024.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。